Figure 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

In vivo and ex vivo immune responses against autologous irradiated tumor cells or tumor-associated antigens. A, Hematoxylin and eosin staining of a skin punch biopsy of the DTH site showing a representative perivascular area of immune infiltration (black arrow). B, Kaplan–Meyer survival curve and median OS according to DTH status. C and D, IFNγ ELISpot of PBMC secretion after stimulation. Total PBMCs (105 per well) from patients at three different time points (before, during, and after treatment) were incubated in the presence of autologous irradiated tumor cells (C) or Brachyury protein (D). Representative plate images for MVX-01-44 PBMC, nonstimulated (left), stimulated with irradiated tumor cells (middle), or with Brachyury protein (right) is depicted in E. The final number of spot-forming units (SFU) was calculated after background subtraction (negative controls). All conditions were run in triplicate. Patient with PR are highlighted in red.